Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

gilead-sciences

EU recommends PrEP in Gilead’s HIV prevention treatment

July 25, 2016
Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention

Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …

News
gilead-sciences

Gilead receives EU approval for combo hepatitis C treatment

July 11, 2016
Sales and Marketing Epclusa, Gilead, eu approval, sofosbuvir

Gilead Sciences (NASDAQ: GILD) has received a marketing authorisation approval from the European Commission for combination treatment Epclusa (sofosbuvir/velpatasvir) for …

News
gilead-sciences

Gilead says US FDA approves Epclusa to treat hepatitis C

June 29, 2016
Research and Development, Sales and Marketing Epclusa, Gilead, HCV, US FDA, drug approval, regulation

US drug firm Gilead Sciences (Nasdaq: GILD) said the US Food and Drug Administration has approved its Epclusa (sofosbuvir/velpatasvir), in …

News
gavel

Judge reverses verdict in MSD/Gilead hepatitis C dispute

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi

A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …

News
gilead-sciences

Gilead names Kevin Young new chief operating officer

May 25, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead

Gilead Sciences (NASDAQ: GILD) has announced two new senior appointments, including Kevin Young as its new chief operating officer. Martin …

Appointment
gilead-sciences

Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies

April 20, 2016
Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir

Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …

News
merck-sharp--dohme-corp

Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials

April 14, 2016
Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier

US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …

News
iqwigsmall

IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition

April 11, 2016
Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV

German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …

News
descovy

FDA approves Gilead’s latest HIV treatment

April 5, 2016
Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …

News
sovaldi-web

Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016
Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …

News
pills-943764_1920

Revealed: analysts predict seven highest-earning pharma blockbusters

February 4, 2016
Sales and Marketing Gilead, OCA, Thomson Reuters, blockbusters, sales

Seven new drugs currently in development will enter the market this year – and earn sales of more than $1 …

News
Gilead logo

Gilead terminates Phase II simtuzumab IPF study

January 6, 2016
Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab

Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …

News
Gilead

Gilead success in late-stage hepatitis B trials

January 5, 2016
Research and Development, Sales and Marketing Gilead, hepatitis B, phase III

Two Phase III trials evaluating Gilead treatments in chronic hepatitis B virus (HBV) infection have met their primary objectives, showing …

News
Gilead sign

Gilead steps in to rescue Galapagos RA drug

December 18, 2015
Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis

Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …

News
Sovaldi bottle

Gilead’s Sovaldi wins Drug Discovery of the Year Award

December 16, 2015
Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi

Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025